Nixon Capital’s Moderna MRNA Stock Holding History

Nixon Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,500	Closed	-$182K	–	24
2023 Q2	$182K	Hold	1,500	–	–	0.09%	22
2023 Q1	$230K	Hold	1,500	–	–	0.14%	20
2022 Q4	$269K	Buy	+1,500	New	+$245K	0.18%	20

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Nixon Capital's MRNA Position: Q3 2023 in Review

Nixon Capital sold out of Moderna (MRNA) in Q3 2023, closing a stake of 1,500 shares — an estimated $182K sold.

Nixon Capital first reported a position in MRNA in Q4 2022 and held it in 3 quarters. The position peaked at $269K in Q4 2022. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

Nixon Capital reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
Nixon Capital sold 1,500 Moderna shares in Q3 2023, an estimated $182K.
Nixon Capital first reported a position in Moderna in Q4 2022 and held it in 3 quarters.
Nixon Capital's Moderna position peaked at $269K in Q4 2022.
889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Nixon Capital's 13F filing for Q3 2023, filed 14 Nov 2023.